Juniper Pharmaceuticals (JNP) Receives Coverage Optimism Score of -0.06

News coverage about Juniper Pharmaceuticals (NASDAQ:JNP) has trended somewhat negative on Friday, according to AlphaOne. The research firm, a service of Accern, identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Juniper Pharmaceuticals earned a media sentiment score of -0.06 on AlphaOne’s scale. AlphaOne also gave media coverage about the specialty pharmaceutical company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the near future.

Separately, TheStreet raised shares of Juniper Pharmaceuticals from a “d+” rating to a “c” rating in a research note on Wednesday, April 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $10.67.

Shares of Juniper Pharmaceuticals (NASDAQ:JNP) traded up 1.27% during trading on Friday, reaching $4.00. 93,829 shares of the company were exchanged. The firm has a 50-day moving average price of $4.58 and a 200-day moving average price of $5.16. The stock has a market capitalization of $43.37 million, a P/E ratio of 7.33 and a beta of 0.25. Juniper Pharmaceuticals has a 1-year low of $3.65 and a 1-year high of $8.00.

Juniper Pharmaceuticals (NASDAQ:JNP) last announced its quarterly earnings results on Tuesday, March 7th. The specialty pharmaceutical company reported $0.88 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.45 by $0.43. Juniper Pharmaceuticals had a negative net margin of 7.44% and a negative return on equity of 9.68%. The firm had revenue of $20.93 million for the quarter, compared to analyst estimates of $15.33 million. Equities research analysts predict that Juniper Pharmaceuticals will post ($0.77) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at

Juniper Pharmaceuticals Company Profile

Juniper Pharmaceuticals, Inc, formerly Columbia Laboratories, Inc, is a women’s health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women’s health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE.

5 Day Chart for NASDAQ:JNP

Receive News & Ratings for Juniper Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply